The Impact of 7-valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease: A Literature Review
Streptococcus pneumoniae can cause invasive pneumococcal diseases (IPD), such as bacteremic pneumonia, bacteremia, meningitis, and sepsis, and non-IPDs, such as otitis media, nonbacteremic pneumonia, and upper respiratory tract infections. It was estimated in 2000 that, worldwide, S. pneumoniae was responsible for 826,000 deaths annually in children aged between 1 month and 5 years. A 7-valent pneumococcal conjugate vaccine (PCV7) was licensed in 2000 in the USA and in 2001 in Europe.
A literature search was performed in PubMed to identify studies assessing the impact of routine childhood PCV7 vaccination on pneumococcal morbidity and mortality. Here, the impact on IPD is reported.
A total of 37 articles reporting impact data on IPD were included in this review: four from Australia, 17 from western Europe, and 16 from North America. In vaccine-eligible children in the postvaccination period, a reduction ranging from 39.9% in Spain to 99.1% in the USA in vaccine-type (VT) IPD incidence, compared with the prevaccination period, was reported in 18 studies. All but one of the 30 studies assessing the impact of PCV7 on all-type IPD reported a reduction ranging from 1.7% in Spain to 76.3% in Australia. In addition, the majority of studies reported reductions in VT and all-type IPD incidence in age groups that were not vaccine eligible.
The results from this review illustrate that PCV7 has had a significant impact on IPD across all ages through its use in pediatric immunization programs. With the introduction of 13-valent pneumococcal conjugate vaccine (PCV13) further reductions in the incidence of IPD due to the six additional serotypes included, as well as continued protection against IPD due to PCV7 serotypes may be expected. Robust surveillance systems are essential for the evaluation of the impact of PCV13 on all-type IPD and for monitoring the evolution of non-VT IPD.
KeywordsDirect vaccine impact Immunology Indirect vaccine impact Infectious diseases Invasive pneumococcal disease Streptococcus pneumoniae Vaccine impact 7-valent pneumococcal conjugate vaccine
- 5.Rosen JB, Thomas AR, Lexau CA, et al. CDC Emerging Infectious Program Network. Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States. Clin Infect Dis. 2011;53:137–143.Google Scholar
- 9.World Health Organization. Pneumococcal conjugate vaccine for childhood immunization — WHO position paper. Wkly Epidemiol Rec. 2007;82:93–104.Google Scholar
- 24.Perez-Trallero E, Marimon JM, Ercibengoa M, Vicente D, Perez-Yarza EG. Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis. 2009;28:731–738.PubMedCrossRefGoogle Scholar
- 25.Foster D, Walker AS, Paul J, et al. Oxford Invasive Penumococcal Surveillance Group. Reduction in invasive pneumococcal disease following implementation of the conjugate vaccine in the Oxfordshire region, England. J Med Microbiol. 2011;60:91–97.Google Scholar
- 32.Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction — eight states, 1998–2005. MMWR Morb Mortal Wkly Rep. 2008;57:144–148.Google Scholar
- 45.Roche PW, Krause V, Cook H, et al. Pneumococcal Working Party of the Communicable Disease Network Australia. Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell. 2008;32:18–30.Google Scholar
- 47.Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage among children aged 19–35 months — United States, 2004. MMWR Morb Mortal Wkly Rep. 2005;54:717–721.Google Scholar
- 49.HM Government. data.gov.uk. NHS Information Centre for Health and Social Care. NHS Immunisation Statistics England 2009-10. London: 2010. Available at: http://data.gov.uk/dataset/nhs-immunisation-statistics-england-2009-10. Accessed Jan 21 2013.
- 50.Lepoutre A, Varon E, Georges S, Gutmann L, Levy-Bruhl D. Impact of pneumococcal conjugate vaccine on the epidemiology of invasive pneumococcal diseases in France - 1998-2010 [in French]. 2010 [cited Jun 14 2012]. Available at: http://www.invs.sante.fr/surveillance/epibac/donnees_2010/pneumocoque_impact_2010.pdf. Accessed Jun 14 2012.Google Scholar
- 51.Office federal de la sante publique et Commission federale pour les vaccinations. Pneumococcal vaccination recommendations for children under five years old. Replacement of 7-valent conjugate vaccine by 13-valent conjugate vaccine [in French]. 2010 [cited Nov 9 2012]; Available from: http://www.bag.admin.ch/themen/medizin/00682/00684/01097/index.html?lang=fr#sprungmarke1_2. Accessed Nov 9 2012.
- 52.Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol. 2010;17:1017–1026.PubMedCrossRefGoogle Scholar